TWD 24.2
(-0.21%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.01 Billion TWD | -11.28% |
2022 | 1.14 Billion TWD | 5.28% |
2021 | 1.08 Billion TWD | -1.33% |
2020 | 1.1 Billion TWD | -9.77% |
2019 | 1.22 Billion TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 1.02 Billion TWD | 0.0% |
2024 Q1 | 1.02 Billion TWD | 1.08% |
2023 Q3 | 1.01 Billion TWD | -7.41% |
2023 FY | 1.01 Billion TWD | -11.28% |
2023 Q1 | 1.09 Billion TWD | -4.19% |
2023 Q2 | 1.09 Billion TWD | 0.0% |
2023 Q4 | 1.01 Billion TWD | 0.0% |
2022 Q3 | 1.14 Billion TWD | 0.0% |
2022 Q4 | 1.14 Billion TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | -11.561% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | -259.361% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | -72.093% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 69.86% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 72.012% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 84.73% |
Center Laboratories, Inc. | 6.78 Billion TWD | 85.038% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | -530.436% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | -13.803% |
InnoPharmax Inc. | 48.64 Million TWD | -1987.052% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | -216.309% |
Excelsior Biopharma Inc. | 472.87 Million TWD | -114.715% |
DV Biomed Co., Ltd. | 765.87 Million TWD | -32.571% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | -64.577% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | -261.48% |
UniPharma Co., Ltd. | 37.4 Million TWD | -2614.714% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | -1234.398% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | -171.569% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -1942.055% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | -833.62% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | -659.83% |